Drug intelligence / Profile preview

CCNU + doxorubicin + vincristine

Development stage: Unknown
Lead developer: Farmitalia
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

CCNU (lomustine) + doxorubicin + vincristine is a chemotherapy combination regimen used in the treatment of various cancers. This combination has been studied in non-small cell lung cancer and lymphomas. The regimen sometimes includes additional agents such as cyclophosphamide (forming the ACCO regimen) or cisplatinum (forming the PACCO regimen). Doxorubicin (also known as adriamycin) is an anthracycline antibiotic with antineoplastic properties, CCNU (lomustine) is a nitrosourea alkylating agent, and vincristine (also known as oncovin) is a vinca alkaloid that disrupts microtubules.

Other names: lomustine + doxorubicin + vincristineACCO

Targets

TOP2A (DNA topoisomerase II)DNAMicrotubule

Beyond the preview

Go deeper on CCNU + doxorubicin + vincristine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CCNU + doxorubicin + vincristine.

Explore the full profile